Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.76 |
| ▸ | CKS1B | P61024 | 2/20 | 0.56 |
| ▸ | SKP1 | P63208 | 2/20 | 0.56 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.50 |
| ▸ | ME2 | P23368 | 1/20 | 0.50 |
| ▸ | ME1 | P48163 | 1/20 | 0.50 |
| ▸ | ME3 | Q16798 | 1/20 | 0.50 |
| ▸ | YAP1 | P46937 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931813 | 1.00 | GPR119 (0.76) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL31286766 | 0.90 | GPR119 (0.64) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL12740686 | 0.89 | GPR119 (0.82) | GPR119ACHETLR9TLR7SLC6A7 | |
| SCHEMBL31287119 | 0.85 | GPR119 (0.65) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL21551197 | 0.85 | GPR119 (0.76) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL2312297 | 0.85 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2SLC6A7 | |
| SCHEMBL5214510 | 0.85 | ME2 (0.57) | GPR119SLC6A7ME2ME1ME3 | |
| SCHEMBL1668645 | 0.85 | GPR119 (0.57) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL25177953 | 0.84 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL30373812 | 0.84 | GPR119 (0.58) | GPR119CKS1BSKP1SKP2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| US-7022728-B2 | Benzimidazoles that are useful in treating male sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-04-04 | — | — | US | disclosed |
| US-6960589-B2 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2005-11-01 | — | — | US | disclosed |
| CN-1516693-A | Benzimidazoles useful in the treatment of sexual dysfunction | ���Ͽع�����˾ | 2004-07-28 | — | — | CN | disclosed |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-07-01 | — | — | US | disclosed |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-06-10 | — | — | US | disclosed |
| EP-1373220-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2003-08-28 | — | — | US | disclosed |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| WO-2002088093-A1 | BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | GPR119 3852/4885CKS1B 185/4885SKP1 2663/4885 |
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | GPR119 2318/4885CKS1B 713/4885SKP1 931/4885 |
| US-20020169167-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | GPR119 433/4885CKS1B 2425/4885SKP1 2632/4885 |
| US-20040127504-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | GPR119 433/4885CKS1B 2425/4885SKP1 2632/4885 |
| US-20020169166-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | GPR119 433/4885CKS1B 2425/4885SKP1 2632/4885 |
| US-20030162790-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | GPR119 433/4885CKS1B 2425/4885SKP1 2632/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | GPR119 3705/4885CKS1B 706/4885SKP1 1839/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | GPR119 2318/4885CKS1B 713/4885SKP1 931/4885 |
| US-20040110766-A1 | Benzimidazoles that are useful in treating sexual dysfunction | CYP19A1, CYP51A1, CYP17A1 | GPR119 433/4885CKS1B 2425/4885SKP1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.